Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKY: Deferiprone in Early Parkinson's Disease
NCT02728843Phase 2Completed
- Sponsor
- ApoPharma Inc.
- Start
- Oct 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of deferiprone in Parkinson's disease (PD) (5 arms), sponsored by ApoPharma Inc. Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III at 9 months. Started Oct 2016; status: completed.
02
Drugs
deferiprone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02728843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728843.